Chan‐Juan Wang

Chan‐Juan Wang

Auto-generated profile, based on publicly available information

Chan‐Juan Wang

Capital Medical University, National Key Discipline of Pediatrics, Beijing, China; Ministry of Education, Key Laboratory of Major Diseases in Children, Beijing, China; National Center for Children's Health, Capital Medical University, Beijing Children's Hospital, Department of Hematology, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
LCLei Cui
Lei Cui
CWChan‐Juan Wang
Chan‐Juan Wang
HLHong‐Yun Lian
Hong‐Yun Lian
LZLi Zhang
Li Zhang
HMHong‐Hao Ma
Hong‐Hao Ma
RZRui Zhang
Rui Zhang

6 June 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
CWChan‐Juan Wang
Chan‐Juan Wang
TZTing Zhu
Ting Zhu
CZChen‐Zi Zhao
Chen‐Zi Zhao
HCHua Cui
Hua Cui
DWDong Wang
Dong Wang
LCLei Cui
Lei Cui

31 March 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
TZTing Zhu
Ting Zhu
CWChan‐Juan Wang
Chan‐Juan Wang
HLHong‐Yun Lian
Hong‐Yun Lian
HMHong‐Hao Ma
Hong‐Hao Ma
DWDong Wang
Dong Wang
ZLZhigang Li
Zhigang Li

2 November 2025 in Jornal de Pediatria
Verified
Journal Article
Open access
HLHua-Lin Li
Hua-Lin Li
HLHong-Yun Lian
Hong-Yun Lian
WGWen-Yu Gong
Wen-Yu Gong
STShuo Tian
Shuo Tian
WLWei-Jing Li
Wei-Jing Li
LCLei Cui
Lei Cui
Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasm in which the inflammatory microenvironment plays a crucial role in the development and progression of disease. The prognostic value of circulating lymphocyte subsets and cytokines remains uncertain. The authors retrospectively analyzed baseline peripheral lymphocyte subsets and serum cytokines in 330 consecutive pediatric patients. Immune profiles were compared across disease extent, clinical events, and biological features. Prognostic associations with progression-free survival (PFS) were tested using univariable and multivariable models. Peripheral immune profiles varied with disease extent. Patients with multisystem risk-organ involvement (MS RO+) had fewer total T and Th1 cells, more CD4⁺ T and B cells, and higher IL-6, IL-10, and IFN-γ. Patients who progressed or relapsed showed a similar pattern, and non-survivors had particularly high IL-10. In the first-line cohort, the proportions of T, B, CD4⁺ T, CD8⁺ T, and Th1 cells, ratios of CD4/CD8 and Th1/Th2, and levels of IL-6, IL-10 predicted progression/relapse, and Youden-derived cut-offs dichotomized with distinct PFS. On multivariable Cox, IL-6, IL-10, Th1/Th2 ratio, RO status, and week-6 responses were independent predictors, and a nomogram model with good predictive capability was formed. IL-10 remained independently prognostic in multisystem LCH; the immune indices were not prognostic in single-system LCH. External validation in 103 patients confirmed risk stratification and model performance with well-calibrated PFS estimates. Baseline peripheral lymphocyte subsets and cytokines carried prognostic information in pediatric LCH. The IL-6, IL-10, and Th1/Th2 profile supported risk stratification and may inform treatment planning.

8 March 2024
Verified
Preprint
Open access
ZLZhigang Li
Zhigang Li
TZTing Zhu
Ting Zhu
CWChanjuan Wang
Chanjuan Wang
HLHong-Yun Lian
Hong-Yun Lian
HMHong-Hao Ma
Hong-Hao Ma
LCLei Cui
Lei Cui
Langerhans cell histiocytosis (LCH) is a rare hematologic neoplasm characterized by the clonal proliferation of Langerhans-like cells. Colony-stimulating Factor 1 receptor (CSF1R) is a membrane-bound receptor that is highly expressed in LCH cells and tumor-associated macrophages. In this study, a soluble form of CSF1R protein (sCSF1R) was identified by plasma proteome profiling, and its role in evaluating LCH prognosis was explored. We prospectively measured plasma sCSF1R levels in 104 LCH patients and 10 healthy children using ELISA. Plasma sCSF1R levels were greater in LCH patients than in healthy controls ( P < 0.001) and significantly differed among the three disease extents, with the highest level in MS RO+ LCH patients ( P < 0.001). Accordingly, immunofluorescence showed the highest level of membrane-bound CSF1R in MS RO+ patients. Furthermore, the plasma sCSF1R concentration at diagnosis could efficiently predict the prognosis of LCH patients treated with standard first-line treatment (AUC =0.782, P < 0.001). Notably, dynamic monitoring of sCSF1R levels could predict relapse early in patients receiving BRAF inhibitor treatment. In vitro drug sensitivity data showed that sCSF1R increased resistance to Ara-C in THP-1 cells expressing ectopic BRAF -V600E. Overall, the plasma sCSF1R level at diagnosis and during follow-up is of great clinical importance in pediatric LCH patients.